Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.

Slides:



Advertisements
Similar presentations
Hypertension – Summary
Advertisements

Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Aminoglycoside-Induced Acute Tubular Necrosis PHCL 442 Lab Discussion 2 Raniah Al-Jaizani M.Sc.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Serum Creatinine Is an Inadequate Screening Test.
Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of a Treatment Strategy Consisting of Pravastatin,
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Omeprazole for the Treatment of Symptomatic.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Irbesartan, an angiotensin type 1 receptor inhibitor,
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reference Values for Self-recorded Blood Pressure:
Date of download: 6/28/2016 From: Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis Ann Intern Med. 2015;162(3):
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.
Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Relationship Between Magnitude of Proteinuria.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Copyright © 2000 American Medical Association. All rights reserved.
Hypertension JNC VIII Guidelines.
Copyright © 2015 American Medical Association. All rights reserved.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Based on work of the PPRNet
Copyright © 2010 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2001 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Robert C. Stanton, MD  American Journal of Kidney Diseases 
From: A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation Ann Intern Med. 1999;130(6):
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
The MDRD Study.
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
Diuretics, Kidney Diseases Urine R&M
Step Care Therapy for Hypertension in Diabetic Patients
Nat. Rev. Cardiol. doi: /nrcardio
Meeting the challenges of the new K/DOQI guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Volume 62, Issue 4, Pages (October 2002)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Volume 53, Issue 6, Pages (June 1998)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.
Presentation transcript:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Possible changes in serum creatinine levels in individuals with normal renal function with volume depletion, heart failure, or bilateral renal artery stenosis started on therapy with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) (A); individuals with abnormal renal function started on therapy with an ACEI or ARB, without conditions noted in case A (B); and individuals with normal renal function started on therapy with an ACEI or ARB (C). Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Effects of an angiotensin-converting enzyme inhibitor (ACEI) on creatinine clearance in 23 patients with type 2 diabetes mellitus who received therapy for an average of 5.6 years. Glomerular filtration rate (GFR) returns toward baseline with good blood pressure (BP) control maintained by treatment with clonidine. Asterisk indicates P<.05 compared with baseline. Bars indicate SD. Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Changes in glomerular filtration rate (GFR) among patients with GFR between 13 and 24 mL/min from the Modification of Dietary Protein in Renal Disease trial as a function of the different levels of proteinuria. Asterisk indicates P<.05 compared with initial fall in GFR; dagger, P<.05 compared with initial GFR from less proteinuric groups. MAP indicates mean arterial pressure. Bars indicate SD. Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Relationship of glomerular filtration rate (GFR) decline to change and serum creatinine level. Persons older than 65 years and adults weighing less than 49.5 kg have much lower GFRs for a given level of serum creatinine compared with the usual reference population. Laboratory (lab) manifestations of renal failure start to occur when the GFR is about 30 mL/min. This may occur at serum creatinine values as low as 177 µmol/L (2 mg/dL). These changes include mild anemia and elevations in serum phosphorus levels. As GFR falls below 20 mL/min, additional problems occur, such as acidosis and a tendency toward hyperkalemia. The lighter shaded area indicates the area of shown protection from clinical trials and the darker shaded area indicates the range of where dialysis is usually required. ACEI indicates agiotensin-converting enzyme inhibitor. Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Risk factors with relative risk (and 95% confidence interval) for developing hyperkalemia from use of angiotensin-converting enzyme inhibitors (ACEI). Adapted from Reardon and Macpherson. Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte Representative changes in heart rate (HR) or glomerular filtration rate (GFR) in response to exercise or protein loading in the presence and absence of a given angiotensin-converting enzyme inhibitor (ACEI). Figure Legend:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Arch Intern Med. 2000;160(5): doi: /archinte A schematic approach to a patient with renal insufficiency started on therapy with an angiotensin-converting enzyme inhibitor (ACEI). Asterisk indicates blood pressure (BP) less than 130/85 mm Hg for those with renal insufficiency or diabetes; double asterisks, if serum creatinine level increases more than 30%, reduce ACEI dose by 50% and add other BP-lowering agents; plus sign, if serum creatinine rise is greater than 30% and less than 50% within the first month of therapy, causes for hypoperfusion are eliminated, and nonsteroidal anti-inflammatory drugs (NSAIDs) are not given, treat as if bilateral renal arterial disease is present. Figure Legend: